ArticleJTCVS open2026
Staged cardiac and pulmonary resection for primary cardiac sarcoma.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Primary cardiac sarcoma is exceptionally rare, and the need for anatomical lung resection to achieve complete removal markedly increases operative risk. To reduce bleeding into the pneumonectomy space and mitigate hazards of single-stage cardiac and pulmonary resections, we adopted a staged strategy performing lung resection only after cardiopulmonary bypass-related coagulopathy has resolved. This study evaluates the outcomes of this approach. Methods: We retrospectively reviewed our institutional cardiac tumor database (April 1998 to October 2025) for primary cardiac sarcomas requiring anatomical lung resection. Fourteen patients underwent the "Texas Two-Step" approach-cardiac sarcoma resection followed by delayed pneumonectomy or lobectomy. Outcomes were compared with a historical cohort who underwent concomitant pneumonectomy during cardiac sarcoma resection (n = 7). Primary end points were operative and 1-, 2-, and 3-year survival, with recurrence as a secondary end point. Results: The median patient age was 42 years. Tumors involved the left atrium with pulmonary venous invasion in 50% and the pulmonary arteries in 50%. Pneumonectomy was required in 78.6%, and lobectomy in 21.4%. R0 resection was achieved in 64.3%. There was no operative mortality compared with 43% in the historical cohort. One-, 2-, and 3-year survival was 64%, 53.5%, and 42.8%, with significantly better survival than controls ( Conclusions: The Texas Two-Step strategy reduces operative mortality and transfusion needs in patients requiring lung resection for cardiac sarcoma and facilitates safer management in high-volume multidisciplinary centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.